Actively Recruiting

Phase 2
Age: 45Years - 85Years
All Genders
NCT04525144

EGb 761 in the Syndrome of MCI With Concomitant CVD

Led by National Neuroscience Institute · Updated on 2022-11-17

134

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

Sponsors

N

National Neuroscience Institute

Lead Sponsor

D

Dr. Willmar Schwabe GmbH & Co. KG

Collaborating Sponsor

AI-Summary

What this Trial Is About

EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.

CONDITIONS

Official Title

EGb 761 in the Syndrome of MCI With Concomitant CVD

Who Can Participate

Age: 45Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with mild cognitive impairment based on the Petersen and Albert MS criteria
  • Global Clinical Dementia Rating Score of 0.5
  • Aged 45 to 85 years at study entry
  • Literate and able to complete cognitive evaluations per investigator opinion
  • Presence of cerebrovascular disease confirmed by white matter hyperintensities of Fazekas grade 2 or 3 on MRI or CT scans done within 12 months prior to recruitment
  • Provided written informed consent to participate
Not Eligible

You will not qualify if you...

  • Receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors, or NMDA antagonists during the study
  • Contraindications for EGb 761 as per local prescribing information or Summary of Product Characteristics (SmPC)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Neuroscience Institute

Singapore, Singapore, 308433

Actively Recruiting

Loading map...

Research Team

J

Joanna Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

EGb 761 in the Syndrome of MCI With Concomitant CVD | DecenTrialz